Patent details

LUC00095 Product Name: Erenumab

Basic Information

Publication number:
LUC00095
Type:
SPC
SPC Type:
Medical
Basic Patent Number:
EP097750723
Legal Status:
Inactive
Application number:
LUC00095
First applicant's nationality:
Procedural language:
French

Marketing Authorization

Marketing Authorization Number:
EU/1/18/1293
Marketing Authorization Type:
Marketing Authorization Date:
30/07/2018
Marketing Authorization Status:
Accepted
Marketing Authorization Country:
Luxembourg (LU)

Dates

Filing date:
20/12/2018
First Marketing Authorization date:
30/07/2018
Grant date:
24/12/2019
Activation date:
Publication date:
28/12/2018
Lapsed date:
Expiration date:
Renunciation date:
Revocation date:
Annulment date:
Basic SPC Expiration:
30/07/2033
SPC Extension Expiration:
30/07/2033
Rejection date:
Withdrawal date:

Owner

From:
20/12/2018
 
 

Name:
Amgen, Inc
Address:
One Amgen Center Drive, Thousand Oaks, CA 91320-1799, United States (US)

Agent

Name:
OFFICE FREYLINGER S.A.
From:
20/12/2018
Address:
Boîte Postale 48, L-8001, STRASSEN, Luxembourg (LU)
To:

Publication

Bulletin

1

Bulletin Heading:
SPC1
Bulletin edition number:
2019/01
Publication date:
09/01/2019
Description:
Section C : Published requests for Supplementary Protection Certificates – I1 publication

2

Bulletin Heading:
SPC2
Bulletin edition number:
2020/01
Publication date:
13/01/2020
Description:
Section D : Granted supplementary protection certificates – I2 publication

Annual Fees

Annual Fee Due Date:
31/12/2029
Annual Fee Number:
21
Annual Fee Amount:
410 Euro
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages
20/12/2018 Application Form 4
24/12/2019 Certificate 1
24/12/2019 Publication 1
28/12/2018 Outgoing Correspondence 1
20/12/2018 General Document 2
28/12/2018 Publication 1
20/12/2018 General Document 56
24/12/2019 Outgoing Correspondence 1